Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36, N.3, and our video podcast, CANCER BUZZ TV.
 
Home / Learn / Immunotherapy / Novel Therapies

Novel Therapies

In May 2019, ACCC and SITC hosted a by-invitation Joint Immuno-Oncology Policy Summit in Washington, D.C. The interdisciplinary discussion focused on next steps in advancing immunotherapy for cancer with a focus on three areas: telehealth, CAR T implications, and care coordination and workforce issues. In this video, summit participants Sarah Murawski, MPAS, PA-C, Hematology/Oncology, Stem Cell Transplant, Cellular Therapy Nocturnist, Vanderbilt Ingram Cancer Center, and Robert Richards, MBA, Administrative Director, Cell Therapy and Transplant, Penn Medicine, UPenn Health System, talk about the future of CAR-T therapy, the need for adequate reimbursement for CAR T, and the potential role telehealth may play in expanding access to this promising new therapy.

 

The Latest Resources

  • Patients Receiving Anti Cancer Immunotherapy
    COVID-19 and Patients Receiving Anticancer Immunotherapy
    By Ryan M. Weight, DO, MS

    SARS-CoV-2 and the resulting respiratory tract infection COVID-19 has upended our society and forcefully changed the way we care for patients. Since the emergence of the virus in early 2020, there have been questions surrounding the risk posed to patients with a cancer diagnosis and the safety of anticancer therapies. 

  • [Publication] Immuno-Oncology in 2020: What We’ve Learned and What Lies Ahead
    In this newly published IO Whitepaper, we take a forward look at how the ACCC IO Institute meets the needs of the evolving multidisciplinary cancer care team and other interdisciplinary providers who may be involved in caring for patients treated with immunotherapies for cancer.
  • Panel takes a deep dive on step therapy in Oncology Article Thumbnail
    Panel Takes a Deep-Dive on Step Therapy in Oncology

    Download a summary of what occured during the ACCC 45th Annual Meeting & Cancer Center Business Summit in March 2019, where a Deep Dive Workshop on Real-World Integration of Immuno-Oncology brought together an expert panel for a focused discussion on step therapy in the context of immunotherapeutics. Panelists explored step therapy from the perspective of different members of the care team, including a patient advocate. 

  • The Oncology Pharmacist's Role in IO Delivery
    By Sarah Hudson-DiSalle, PharmD, RPh

    Are you leveraging the assets of your oncology pharmacists in delivery of immunotherapy for cancer? Oncology pharmacists multidisciplinary team members who help bridge the gap between science and real-world medical practice. Sarah Hudson-DiSalle, PharmD, RPh, describes how your IO program can make the best use of the oncology pharmacist's diverse skillset.  

From Oncology Issues

  •  The Evolving Immunotherapeutic Landscape in Renal Cell Carcinoma
    Robert A. Figlin, MD, FACP; Jocelyn Mohs, PharmD, BCOP; and Laura S. Wood, RN, MSN, OCN
    In 2019 the Association of Community Cancer Centers developed an education program to provide all members of the multidisciplinary care team knowledge and resources to help successfully integrate immunotherapies into the treatment of patients with RCC.
  •  Management of Hospital Admissions for Checkpoint Inhibitor Immune-Related Adverse Events at a Regional Cancer Center
    Andrew Li, PharmD, and Michela Altergott, PharmD
  •  Education Interventions Improve Management of irAEs, Study Shows
  •  Highlights from a Virtual ASCO 2020
    Cary A. Presant, MD, FACP, FASCO
    Listed are my highlights of the ASCO 2020 abstracts, which were chosen if they were a practice-changing study or trial with important new advances.
  •  Virtual Toxicity Team Cleveland Clinic
    This article explores how Cleveland Clinic is taking a unique approach to recruiting specialists outside the field of oncology to participate in immunotherapy multispecialty immune-related adverse events (irAE) tumor boards.
  •  Virtual Toxicity Team Jefferson Health
    This article explores how Jefferson Health is taking a unique approach to recruiting specialists outside the field of oncology to participate in an Immuno-oncology Working Group.
  •  Virtual Toxicity Team Johns Hopkins University
    This article explores Johns Hopkins University’s unique approach to recruiting specialists outside the field of oncology to participate in its virtual immune-related Toxicity Team.
  •  Elevating Survivorship: Results from Two National Surveys
    In order to explore experiences and needs concerning cancer survivorship from both the provider and the patient perspectives, ACCC and NCCS partnered to field two online surveys to oncology providers and cancer survivors, respectively.
  •  A Physician Champion Takes a Practice-Based Immunotherapy Program to the Next Level
    Tracy Virgilio, RN, MSN, OCN
    Early symptom management is key to improving quality of life for patients with cancer, and proactive monitoring delivers unparalleled survival advantage while decreasing emergency visits and admissions. However, immunotherapies require special attention and procedures. Sidney Kimmel Cancer Center earned a 2018 ACCC Innovator Award for their immunotherapy triage algorithms, which provide non-oncology physicians and nurses with the tools to manage IO patients and prevent unnecessary admissions.
  •  Immuno-Oncology: Breaking Barriers, Exploring Solutions, Improving Patient Care
    The ACCC Immuno-Oncology Institute developed a multidisciplinary curriculum workshop bringing together faculty experienced in delivery of immunotherapy with cancer program staff in the earlier stages of IO integration. Over the past two years, these IO Visiting Experts Programs were hosted by ACCC Cancer Program Members nation-wide.
  •  Best Practices for Implementing Cancer Immunotherapy in the Community
    The Association of Community Cancer Centers (ACCC) recently hosted live continuing medical education (CME)-certified learning workshops at two community cancer programs to review current barriers to immunotherapy implementation in the community setting. During the workshops, an expert faculty panel engaged participants in discussion on the challenges that they may face as they integrate immunotherapy into their clinical practice, as well as practical solutions and strategies they can apply to overcome these barriers. This article summarizes the guidance and information provided by the faculty on the various issues raised during the workshop discussions.
  •  Highlights from ASCO 2018
    By Cary A. Presant, MD, FACP, FASCO
    ASCO 2018 offered a wealth of new data that will continue to transform clinical practice and cancer program development. Most important, implementation of the scientifi c advances we learned at ASCO 2018 will improve the length and quality of life of our cancer patients.
  •  Turning on the Light Switch
    By Ann McGreal, RN
    Discover how 2017 ACCC Innovator Award winner Advocate Medical Group developed and implemented an immunotherapy program, lessons learned, and tools created to educate staff and patients.
  •  Best of ASCO 2017
    Cary A. Presant, MD, FACP, FASCO
    ASCO 2017 was filled with new information and long lines as 39,000 oncologists worldwide came together to hear the latest advances in cancer care.
  •  Real-World Experiences in Immunotherapy Delivery
    The ACCC education project, “Real-World Experiences in Immunotherapy Delivery,” addresses some of the practical issues that cancer programs must navigate to provide immunotherapy safely and effectively in their own communities.
  •  Advancing Immuno-Oncology in the Community Setting
    Steven Powell, MD
    As cancer treatment evolves with the emergence of genomics, personalized therapies, and immunotherapies, care delivery must also transform.

On-Demand Webinars

  • Learn how the microbiome could potentially be used to predict and enhance response to I-O therapy and to recognize patients who could be at risk for developing immune-related adverse events.

Blog Posts